Live

Watch CBSN Live

Allergan Gets on the GSK Merry-Go-Round for a Second Time

Shares of Allergan have risen in the last few days on the rumor that GlaxoSmithKline may be interested in buying the company. BNET discussed this scenario back in March. Do the Q2 2009 results for both companies help clarify the case, for or against, such a deal?
Certainly, GSK's situation looks more desperate than it did in Q1, especially when you see this chart of expected revenue losses from generic competition.

As for Allergan, the double-whammy of recession and competition from Medicis' version of Botox, Dysport, depressed its revenues by 3.2 percent. (Just to prove the point, Medicis' revenues were up 3 percent to $141 million.) Thirty percent of Allergan's sales are Botox -- that's what's at stake.

So the situation for both companies is deteriorating, but at a slower pace for Allergan than for GSK.

Ancient history: Combining these two companies would bring them both full circle for a second time. The Orange County Business Journal notes that GSK's predecessor, SmithKline Beecham, acquired Allergan in the 1980s and then spun it off again.